WallStSmart

Im Cannabis Corp (IMCC)vsZoetis Inc (ZTS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Zoetis Inc generates 20696% more annual revenue ($9.53B vs $45.80M). ZTS leads profitability with a 27.7% profit margin vs -39.1%. ZTS earns a higher WallStSmart Score of 58/100 (C).

IMCC

Avoid

31

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 3/9Altman Z: -11.55

ZTS

Buy

58

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 5.3Quality: 7.0
Piotroski: 4/9Altman Z: 3.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IMCCUndervalued (+82.8%)

Margin of Safety

+82.8%

Fair Value

$6.85

Current Price

$0.75

$6.10 discount

UndervaluedFair: $6.85Overvalued
ZTSUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$143.36

Current Price

$83.18

$60.18 discount

UndervaluedFair: $143.36Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IMCC1 strengths · Avg: 10.0/10
Debt/EquityHealth
-2.5010/10

Conservative balance sheet, low leverage

ZTS5 strengths · Avg: 9.4/10
Return on EquityProfitability
83.1%10/10

Every $100 of equity generates 83 in profit

Operating MarginProfitability
40.7%10/10

Strong operational efficiency at 40.7%

Altman Z-ScoreHealth
3.1410/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
27.7%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
12.9x8/10

Attractively priced relative to earnings

Areas to Watch

IMCC4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.52M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-119.8%2/10

ROE of -119.8% — below average capital efficiency

ZTS4 concerns · Avg: 3.0/10
Price/BookValuation
10.9x4/10

Trading at 10.9x book value

EPS GrowthGrowth
1.2%4/10

1.2% earnings growth

PEG RatioValuation
14.562/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : IMCC

The strongest argument for IMCC centers on Debt/Equity.

Bull Case : ZTS

The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 27.7% and operating margin at 40.7%.

Bear Case : IMCC

The primary concerns for IMCC are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : ZTS

The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.

Key Dynamics to Monitor

IMCC profiles as a turnaround stock while ZTS is a declining play — different risk/reward profiles.

IMCC carries more volatility with a beta of 2.21 — expect wider price swings.

ZTS is growing revenue faster at -0.2% — sustainability is the question.

ZTS generates stronger free cash flow (538M), providing more financial flexibility.

Bottom Line

ZTS scores higher overall (58/100 vs 31/100), backed by strong 27.7% margins. IMCC offers better value entry with a 82.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Im Cannabis Corp

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

IM Cannabis Corp. The company is headquartered in Tel Aviv-Yafo, Israel.

Visit Website →

Zoetis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.

Visit Website →

Want to dig deeper into these stocks?